Among the innately lapatinib insensitive cell lines, clinico-pathological subtype of MDA-MB-453 is fiercely debated in literature, while some suggest it is a triple negative BC cell with no or low HER2 expression [82], others reports it to be HER2 positive with overexpressed HER2 [83]. The gene discussed is ERBB2; the disease is breast cancer.